Agerafenib (RXDX-105)

For research use only. Not for use in humans.

目录号:S8015 别名: CEP-32496

Agerafenib (RXDX-105) Chemical Structure

CAS No. 1188910-76-0

Agerafenib (RXDX-105, CEP-32496) 是一种高度有效的BRAF(V600E/WT)c-Raf抑制剂,Kd为14 nM/36 nM和39 nM,适度有效作用于Abl-1, c-Kit, RET (c-RET), PDGFRβ和VEGFR2,对MEK-1, MEK-2, ERK-1和ERK-2具有微弱的亲和力。Phase 1/2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 4583.55 现货
RMB 2200.97 现货
RMB 16298.1 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Agerafenib (RXDX-105)发表文献6篇:

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述 Agerafenib (RXDX-105, CEP-32496) 是一种高度有效的BRAF(V600E/WT)c-Raf抑制剂,Kd为14 nM/36 nM和39 nM,适度有效作用于Abl-1, c-Kit, RET (c-RET), PDGFRβ和VEGFR2,对MEK-1, MEK-2, ERK-1和ERK-2具有微弱的亲和力。Phase 1/2。
特性 对BRAF(V600E)突变型和相关的c-Raf具有高的结合亲和力,而对MAPK通路的其它关键激酶,包括MEK-1,MEK-2,ERK-1和ERK-2无显著的亲和力。
靶点
c-Kit [1] LCK [1] PDGFRβ [1] RET [1] Abl1 [1]
2 nM(Kd) 2 nM(Kd) 2 nM(Kd) 2 nM(Kd) 3 nM(Kd)
体外研究

CEP-32496抑制A375细胞(BRAFV600E) 增殖, EC50为78 nM。CEP-32496作用于肿瘤细胞系,对表达突变型BRAF的A375, SK-MEL-28, Colo-205, Colo-679, 和HT-144细胞比表达野生型BRAF的HCT116, Hs578T, LNCaP, DU145, 和PC-3细胞具有更敏感的细胞毒性作用。[1]CEP-32496作用于人类黑色素瘤(A375)和结肠直肠癌(Colo-205)细胞系,抑制MAPK/MEK磷酸化,IC50分别为 78 nM 和 60 nM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 MVfGeY5kfGmxbjDhd5NigQ>? MkHENUBpeg>? MnfZTY5pcWKrdHnvckBw\iCOQ1ugbY4hcHWvYX6gTGVMOjl|IHPlcIx{KGGodHXyJFEhcHJiYomgZ49ueGW2aYTpc44h[mmwZHnu[{Bie3OjeTygT4Q:OC5yMENOwG0v Mle4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNki2NlYoRjJ{MU[4OlI3RC:jPh?=
HEK293 MYrGeY5kfGmxbjDhd5NigQ>? MoTwNUBpeg>? Mni0TY5pcWKrdHnvckBw\iCSRFfGVoJmfGFiaX6gbJVu[W5iSFXLNlk{KGOnbHzzJIFnfGW{IEGgbJIh[nliY3;tdIV1cXSrb36gZolv\GmwZzDhd5NigSxiS3S9NE4xODMQvF2u NEDuOmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PFYzPid-MkKxOlg3OjZ:L3G+
HEK293 MojmSpVv[3Srb36gZZN{[Xl? M3Pt[VEhcHJ? NXTHVnhHUW6qaXLpeIlwdiCxZjDjT4l1KGmwIHj1cYFvKEiHS{K5N{Bk\WyuczDh[pRmeiBzIHjyJIJ6KGOxbYDleIl1cW:wIHLpcoRqdmdiYYPzZZktKEumPUCuNFAz|ryPLh?= MlXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNki2NlYoRjJ{MU[4OlI3RC:jPh?=
HEK293 NFn0c3hHfW6ldHnvckBie3OjeR?= MWKxJIhz MVzJcohq[mm2aX;uJI9nKFKndDDpckBpfW2jbjDISWszQTNiY3XscJMh[W[2ZYKgNUBpeiCkeTDjc41x\XSrdHnvckBjcW6maX7nJIF{e2G7LDDL[F0xNjByMt88UU4> NFzicWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PFYzPid-MkKxOlg3OjZ:L3G+
HEK293 NWfGdVlOTnWwY4Tpc44h[XO|YYm= MlqxNUBpeg>? M13VdGlvcGmkaYTpc44hd2ZiQXLsNUBqdiCqdX3hckBJTUt{OUOgZ4VtdHNiYX\0[ZIhOSCqcjDifUBkd22yZYTpeIlwdiCkaX7kbY5oKGG|c3H5MEBM\D1yLkCwN:69VS5? MojvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNki2NlYoRjJ{MU[4OlI3RC:jPh?=
HEK293 Mn;CSpVv[3Srb36gZZN{[Xl? NYfrPVk6OSCqch?= NF21ZZdKdmirYnn0bY9vKG:oIG\FS2ZTOiCrbjDoeY1idiCKRVuyPVMh[2WubIOgZYZ1\XJiMTDodkBjgSClb33w[ZRqfGmxbjDibY5lcW6pIHHzd4F6NCCNZE2wMlAxQM7:TT6= M361RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[4OlI3Lz5{MkG2PFYzPjxxYU6=
HEK293 MYLGeY5kfGmxbjDhd5NigQ>? MlP0NUBpeg>? NIrobWRKdmirYnn0bY9vKG:oIFPTSlFTKGmwIHj1cYFvKEiHS{K5N{Bk\WyuczDh[pRmeiBzIHjyJIJ6KGOxbYDleIl1cW:wIHLpcoRqdmdiYYPzZZktKEumPUCuNFA6|ryPLh?= NYLWd|dWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlg3OjZpPkKyNVY5PjJ4PD;hQi=>
HEK293 NHqxfIxHfW6ldHnvckBie3OjeR?= Mk[2NUBpeg>? NWLCTGltUW6qaXLpeIlwdiCxZjDFVGhCOiCrbjDoeY1idiCKRVuyPVMh[2WubIOgZYZ1\XJiMTDodkBjgSClb33w[ZRqfGmxbjDibY5lcW6pIHHzd4F6NCCNZE2wMlAyPM7:TT6= MortQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNki2NlYoRjJ{MU[4OlI3RC:jPh?=
HEK293 MU\GeY5kfGmxbjDhd5NigQ>? MVqxJIhz M1uwSGlvcGmkaYTpc44hd2ZiQmLBSkBXPjByRTDteZRidnRiaX6gbJVu[W5iSFXLNlk{KGOnbHzzJIFnfGW{IEGgbJIh[nliY3;tdIV1cXSrb36gZolv\GmwZzDhd5NigSxiS3S9NE4xOTUQvF2u NHnjW4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PFYzPid-MkKxOlg3OjZ:L3G+
HEK293 NXzvO5RzTnWwY4Tpc44h[XO|YYm= MUCxJIhz NEP3bm1KdmirYnn0bY9vKG:oIFXHSnIhcW5iaIXtZY4hUEWNMkmzJINmdGy|IHHmeIVzKDFiaIKgZpkh[2:vcHX0bZRqd25iYnnu[Ilv\yCjc4PhfUwhU2R;MD6wNlLPxE1w MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OE[yOkc,OjJzNki2NlY9N2F-
HEK293 MnLOSpVv[3Srb36gZZN{[Xl? NV\ofXlvOSCqch?= MoHBTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViQmLBSkBqdiCqdX3hckBJTUt{OUOgZ4VtdHNiYX\0[ZIhOSCqcjDifUBkd22yZYTpeIlwdiCkaX7kbY5oKGG|c3H5MEBM\D1yLkCzOu69VS5? NUSxO2FyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlg3OjZpPkKyNVY5PjJ4PD;hQi=>
COLO205 NVnqbJFES3m2b4TvfIlkcXS7IHHzd4F6 NYXXRmxTPzJiaILz M3XGZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNQVE9{MEWgZ4VtdHNiZYjwdoV{e2mwZzDCVmFHKFZ4MEDFJI12fGGwdDDh[pRmeiB5MjDodpMh[nliY3XscEB1cXSncjDicJVmKGG|c3H5MEBGSzVyPUCuNFM3|ryPLh?= NV75cFFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlg3OjZpPkKyNVY5PjJ4PD;hQi=>
HEK293 Ml\aSpVv[3Srb36gZZN{[Xl? NVnnTFN6OSCqch?= MlXETY5pcWKrdHnvckBw\iCFUlHGJIlvKGi3bXHuJGhGUzJ7MzDj[YxteyCjZoTldkAyKGi{IHL5JINwdXCndHn0bY9vKGKrbnTpcoch[XO|YYmsJGtlRTBwMEO5{txONg>? NEfWbHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PFYzPid-MkKxOlg3OjZ:L3G+
A375 M2\LVGN6fG:2b4jpZ4l1gSCjc4PhfS=> NFLjT2s4OiCqcoO= MnWzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVM4PSClZXzsd{BmgHC{ZYPzbY5oKEKUQV[gWlYxOEVibYX0ZY51KGGodHXyJFczKGi{czDifUBk\WyuIITpeIVzKGKudXWgZZN{[XluIFnDOVA:OC5yN{lOwG0v MoDuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNki2NlYoRjJ{MU[4OlI3RC:jPh?=
A375 MkXGSpVv[3Srb36gZZN{[Xl? NHLGSnkzKGi{cx?= MVzJcohq[mm2aX;uJI9nKEKUQV[gWlYxOEVibYX0ZY51NW2nZHnheIVlKE2HSzDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iQUO3OUBk\WyuczDh[pRmeiB{IHjyd{whUUN3ME2wMlA5Os7:TT6= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OE[yOkc,OjJzNki2NlY9N2F-
HCC827 MmD3SpVv[3Srb36gZZN{[Xl? NHTJTY1FcXOybHHj[Y1mdnRib3[gX|NJZS2leXPsc5BidWmwZTDmdo9uKFOPTzDWOFA1VSCvdYThcpQhcW5iZ3XmbZRqdmmkIILld4l{fGGwdDDoeY1idiCKQ1O4Nlch[2WubIOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygT4k:OC5zOEe4{txONg>? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd6N{G1Okc,Ojh5OEexOVY9N2F-
COLO679 NH\uVotEgXSxdH;4bYNqfHliYYPzZZk> MXG3NkBpenN? NIjBbXZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEV0yRNke5JINmdGy|IHX4dJJme3OrbnegRnJCTiCYNkCwSUBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IHPlcIwhfGm2ZYKgZox2\SCjc4PhfUwhTUN3ME2wMlIyOc7:TT6= NUHlWplzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlg3OjZpPkKyNVY5PjJ4PD;hQi=>
HT144 NHGyT5dEgXSxdH;4bYNqfHliYYPzZZk> MkP5O|IhcHK| NUf3[XRTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRzNESgZ4VtdHNiZYjwdoV{e2mwZzDCVmFHKFZ4MEDFJI12fGGwdDDh[pRmeiB5MjDodpMh[nliY3XscEB1cXSncjDicJVmKGG|c3H5MEBGSzVyPUCuNlI5|ryPLh?= NUf6WGVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlg3OjZpPkKyNVY5PjJ4PD;hQi=>
SK-MEL-28 NXvSdVlXS3m2b4TvfIlkcXS7IHHzd4F6 NX7teW9{PzJiaILz MofSR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2suVUWOLUK4JINmdGy|IHX4dJJme3OrbnegRnJCTiCYNkCwSUBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IHPlcIwhfGm2ZYKgZox2\SCjc4PhfUwhTUN3ME2wMlQ2PM7:TT6= MmXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNki2NlYoRjJ{MU[4OlI3RC:jPh?=
HEK293 MYTGeY5kfGmxbjDhd5NigQ>? NXyyXHFvOSCqch?= MYHJcohq[mm2aX;uJI9nKGOPRWSgbY4hcHWvYX6gTGVMOjl|IHPlcIx{KGGodHXyJFEhcHJiYomgZ49ueGW2aYTpc44h[mmwZHnu[{Bie3OjeTygT4Q:OC53MUROwG0v MmLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNki2NlYoRjJ{MU[4OlI3RC:jPh?=
HCT116 M{HyZmN6fG:2b4jpZ4l1gSCjc4PhfS=> MUO3NkBpenN? NYHX[JBRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJGJTSUZiYX\0[ZIhPzJiaILzJIJ6KGOnbHygeIl1\XJiYnz1[UBie3OjeTygSWM2OD1yLk[2Pe69VS5? NUCyNpRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlg3OjZpPkKyNVY5PjJ4PD;hQi=>
Hs578T Mn;FR5l1d3SxeHnjbZR6KGG|c3H5 MmqxO|IhcHK| NIHZNIhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJezV5OGSgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRnJCTiCjZoTldkA4OiCqcoOgZpkh[2WubDD0bZRmeiCkbIXlJIF{e2G7LDDFR|UxRTJwN{O2{txONg>? MmfrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNki2NlYoRjJ{MU[4OlI3RC:jPh?=
DU145 NHnhcZhEgXSxdH;4bYNqfHliYYPzZZk> M3HXZ|czKGi{cx?= MnXhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQmLBSkBi\nSncjC3NkBpenNiYomgZ4VtdCC2aYTldkBjdHWnIHHzd4F6NCCHQ{WwQVIvQTFzzszNMi=> M4C2bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[4OlI3Lz5{MkG2PFYzPjxxYU6=
HEK293 Mor6SpVv[3Srb36gZZN{[Xl? MmfWNUBpeg>? M2TmOWlvcGmkaYTpc44hd2ZiSlHLNkBqdiCqdX3hckBJTUt{OUOgZ4VtdHNiYX\0[ZIhOSCqcjDifUBkd22yZYTpeIlwdiCkaX7kbY5oKGG|c3H5MEBM\D12LkhOwG0v MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OE[yOkc,OjJzNki2NlY9N2F-
PC3 NUnSU4d[S3m2b4TvfIlkcXS7IHHzd4F6 M2m4[|czKGi{cx?= NUn6OpMzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLSRWYh[W[2ZYKgO|IhcHK|IHL5JINmdGxidHn0[ZIh[my3ZTDhd5NigSxiRVO1NF03NjJ3N988UU4> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OE[yOkc,OjJzNki2NlY9N2F-
LNCAP NWjQVXZ3S3m2b4TvfIlkcXS7IHHzd4F6 MlTBO|IhcHK| M{TZd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxPS0GSIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLSRWYh[W[2ZYKgO|IhcHK|IHL5JINmdGxidHn0[ZIh[my3ZTDhd5NigSxiRVO1NF03NjZ|Md88UU4> MkDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNki2NlYoRjJ{MU[4OlI3RC:jPh?=
HEK293 MlSzSpVv[3Srb36gZZN{[Xl? MojFNUBpeg>? NUe0VGN5UW6qaXLpeIlwdiCxZjDNSWsyKGmwIHj1cYFvKEiHS{K5N{Bk\WyuczDh[pRmeiBzIHjyJIJ6KGOxbYDleIl1cW:wIHLpcoRqdmdiYYPzZZktKEumPUeuNe69VS5? NFWz[4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PFYzPid-MkKxOlg3OjZ:L3G+
HEK293 M3;QdGZ2dmO2aX;uJIF{e2G7 NXLDR|J5OSCqch?= M3LQd2lvcGmkaYTpc44hd2ZiTVXLNkBqdiCqdX3hckBJTUt{OUOgZ4VtdHNiYX\0[ZIhOSCqcjDifUBkd22yZYTpeIlwdiCkaX7kbY5oKGG|c3H5MEBM\D16LkROwG0v MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OE[yOkc,OjJzNki2NlY9N2F-
COLO205 MW\BcpRqfHWvb4KgZZN{[Xl? M{nVZlExKG2pL3vn M3rDTVE1KGSjeYO= MVXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFT1zPNlA2KGOnbHzzJJhmdm:pcnHmeIVlKGmwIHH0bJlucWNiboXk[UBud3W|ZTDheEAyOCCvZz;r[{wheG9iYnnkJIZweiBzNDDkZZl{ NVzmZWFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlg3OjZpPkKyNVY5PjJ4PD;hQi=>
COLO205 MVfBcpRqfHWvb4KgZZN{[Xl? MnOxN|AhdWdxa3e= MknkNVQh\GG7cx?= MoDLRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1;MU|IxPSClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDheIh6dWmlIH71[IUhdW:3c3WgZZQhOzBibXevb4ctKHCxIHLp[EBnd3JiMUSg[IF6ew>? NFj4WYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PFYzPid-MkKxOlg3OjZ:L3G+
COLO205 MnvqRY51cXS3bX;yJIF{e2G7 Mo\uNVAxKG2pL3vn NGXhXlUyPCCmYYnz MWTBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFT1zPNlA2KGOnbHzzJJhmdm:pcnHmeIVlKGmwIHH0bJlucWNiboXk[UBud3W|ZTDheEAyODBibXevb4ctKHCxIHLp[EBnd3JiMUSg[IF6ew>? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OE[yOkc,OjJzNki2NlY9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Growth inhibition assay
Cell viability; 

PubMed: 31695841     


Cell viability was assessed with alamarBlue assays performed after 72 hours of incubation with RXDX-105, and dose-response curves (left) and calculated IC50 values (right) are shown.

31695841
Western blot
p-RET / RET / p-PLCγ / PLCγ / p-ERK / ERK / p-MEK / MEK ; 

PubMed: 28011461     


Inhibition of phosphorylation of RET and downstream pathways by RXDX-105 in TT cells (RET C634W). 

28011461
体内研究 CEP-32496处理小鼠,狗,猴和人肝微粒制品,具有良好的稳定性,测量的内在清除率为<23 (μL/min)/mg,t1/2为>60 分钟。CEP-32496按30 mg/kg剂量口服处理给药携带Colo-205移植瘤的小鼠模型,每天两次,肿瘤生长停滞,部分肿瘤消退(PRs)的发生率为40%,而按100 mg/kg剂量处理,则肿瘤生长停滞,部分肿瘤消退(PRs)的发生率为80%。CEP-32496按30 mg/kg剂量口服处理肿瘤裂解物,每天两次,在给药时间点厚2小时和6小时,分别抑制50%和75%归一化的pMEK,而按55 mg/kg剂量处理给药携带Colo-205移植瘤的小鼠模型, 抑制57%到75%pMEK。[1]CEP-32496处理多个临床前物种具有良好的口服生物利用度(大鼠,狗和猴> 95%)。CEP-32496(100 mg/kg)处理携带BRAF(V600E)结肠癌移植瘤的裸鼠,抑制pMEK和pERK,使肿瘤持续生长停滞和衰退。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

结合实验:

结合反应在室温下进行1小时,通过捕获固定化的亲和配体,测定未与实验化合物结合的激酶组分,通过定量PCR检测进行定量分析。分别测定CEP-32496作用于每种激酶的效果。使用11种连续3倍稀释液测定Kd值,并表示为实验按一式两份进行的平均值。各个值之间的变异性小于2倍。
细胞实验:[1]
- 合并
  • Cell lines: A375 细胞系
  • Concentrations: 78 nM
  • Incubation Time: 72 小时
  • Method: 细胞按每孔104个细胞接种在含10%胎牛血清的DMEM培养基中进行培养。使用PBS洗涤细胞,更换为含0.5%血清的DMEM培养基,温育过夜。加入不同浓度CEP-32496,DMSO 终浓度为0.5%,温育72小时。温育末期,加入Cell Titer Blue,再温育3小时。使用SoftMax Pro (激发波长为560 nm,发射波长为590 nm) 测量荧光信号的强度,对剩余的存活细胞进行定量。使用含有Igor Pro 的9点曲线推算IC50值,并且表示为实验按一式两份进行的平均值。各个值之间的变异性小于2倍。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 携带Colo-205移植瘤的小鼠模型
  • Dosages: 100 mg/kg
  • Administration: 口服饲喂
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 9 mg/mL (17.39 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
15% Captisol
15 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 517.46
化学式

C24H22F3N5O5

CAS号 1188910-76-0
储存条件 粉状
溶于溶剂
别名 CEP-32496

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Raf Signaling Pathway Map

相关Raf产品

Tags: 购买Agerafenib (RXDX-105) | Agerafenib (RXDX-105)供应商 | 采购Agerafenib (RXDX-105) | Agerafenib (RXDX-105)价格 | Agerafenib (RXDX-105)生产 | 订购Agerafenib (RXDX-105) | Agerafenib (RXDX-105)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID